{"analyses":[{"ciLowerLimit":"1.017","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.421","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0243","paramType":"Hazard Ratio (HR)","paramValue":"1.202","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.00","upperLimit":"4.00","value":"4.00"},{"groupId":"OG001","lowerLimit":"3.00","upperLimit":"4.00","value":"3.00"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"354"},{"groupId":"OG001","value":"357"}],"units":"Participants"}],"description":"Time to resolution of fever in participants with fever at baseline was calculated using cox proportional hazard regression model adjusted for baseline disease severity (OS 4, OS 5, OS 6), age (\\<65 years, \\>=65 years), region (United States, Europe, rest of world), and systemic corticosteroids used at baseline for primary study condition (Yes/No).","dispersionType":"95% Confidence Interval","groups":[{"description":"Placebo administered orally QD with standard of care.","id":"OG000","title":"Placebo + SOC"},{"description":"4 mg baricitinib administered orally QD with standard of care.","id":"OG001","title":"Baricitinib + SOC"}],"paramType":"MEDIAN","populationDescription":"All participants randomly assigned to study intervention who had a fever at baseline.","reportingStatus":"POSTED","timeFrame":"Day 1 to Day 28","title":"Time to Resolution of Fever in Participants With Fever at Baseline","type":"SECONDARY","unitOfMeasure":"days"}